Project Grant RM1DA063351
Award Date
7/15/25
Completion Date
3/31/30
Dollars Obligated
$2M
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The National Institute on Drug Abuse (NIDA) awarded a $687,416 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco, CA. The grant supports research to develop therapeutically effective latency-promoting agents (LPAs) that can "block" HIV reactivation and "lock" HIV in a silenced state, even in the presence of addictive substances, for people living...
This Project Grant award of $2,331,737 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a comprehensive study to investigate the impact of methamphetamine (MA) use on HIV persistence, immune dysfunction, and clinical outcomes among people living with HIV (PWH) on antiretroviral therapy (ART). The study will leverage three unique cohorts to perform the first-in-human investigations directly quantifying MA concentrations in...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,032,192 to Yale University to conduct research on the cell-type specific epigenomic effects of cannabis use in people living with HIV. The project aims to dissect the interactions between HIV infection and cannabis use, and identify potential druggable targets through comprehensive profiling of DNA methylation across different cell types. The...
This federal Project Grant award for $263,119 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) is focused on developing NLRP3 inhibitors to address HIV-associated neuroinflammation in cocaine use. The key objectives are to computationally design, synthesize, and screen novel analogues of a lead compound, AMS-17, to improve its biological activity and maintain low toxicity. The project involves in vitro and in vivo screening of...
This federal Project Grant award, totaling $2,812,966.00, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The award supports research investigating the impacts of drug abuse-mediated inflammatory perturbations on the affinity maturation of anti-CD4 autoantibodies and poor immune reconstitution from antiretroviral therapy (ART) in individuals with HIV. Specifically, the research aims to determine the mechanisms of...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,223,769 to the University of California, San Diego (UCSD) to conduct research on the intertwined mechanisms of HIV and opioid use on mitochondrial-mediated inflammasome activation and neurotoxicity. The research aims to elucidate how the convergence of HIV infection and opioid use leads to more severe neurological consequences, including...
This Project Grant award of $558,668 from the National Institute on Drug Abuse (NIDA) under CFDA Program 93.279 - Drug Use and Addiction Research Programs supports research to elucidate the shared and distinct molecular mechanisms underlying the interplay between HIV, substance use disorders (SUD), and neuropsychiatric/neurodegenerative conditions. The award to Massachusetts Institute of Technology (MIT) aims to leverage single-cell transcriptomic, epigenomic, and spatial datasets along with...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $1,475,580 to The Regents of the University of California, San Francisco (UCSF) to conduct in-depth spatial characterization of HIV-host cellular interactions within the central nervous system (CNS) of people living with HIV (PWH) who died suddenly. The key objectives are to: (1) implement innovative spatial multi-omic assays to analyze the...
This $196,350 Project Grant was awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to Yale University. The grant will fund a project titled "HIV COMPLEX CAUSAL MODELING: GUT MICROBIOME, DRUG USE, AND IMMUNE RESPONSES" from August 1, 2024 to July 31, 2026. The project aims to elucidate the causal relationship between drug use disorders, HIV acquisition, gut microbiome, and immune responses using Mendelian randomization...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $1,481,760 to Emory University to study how methamphetamine (MA) use impacts immune dysfunction in people living with HIV (PWH) on antiretroviral therapy (ART). The 5-year award will leverage existing longitudinal blood samples and collect new blood and cerebrospinal fluid samples to investigate a multi-step process by which MA promotes...